
Dmitry Nevozhay, M.D., Ph.D.
Department of Imaging Physics, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
2006 | Institute of Immunology and Experimental Therapy, Warsaw, PL, Experimental Oncology, Ph.D |
2002 | Vladivostok State Medical University, Vladivostok, RU, Medicine, M.D |
Postgraduate Training
2007-2012 | Postdoctoral Fellowship, Synthetic Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
2007-2007 | Postdoctoral Fellowship, Experimental Oncology, Institute of Immunology and Experimental Therapy, Wroclaw |
Experience & Service
Academic Appointments
Instructor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2020 - 2022
Research Scientist, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX, 2017 - 2020
Principal Scientist, Far Eastern Federal University, School of Biomedicine, Vladivostok, 2014 - 2022
Instructor, Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2012 - 2014
Docent, Far Eastern Federal University, Vladivostok, 2012 - 2014
Administrative Appointments/Responsibilities
Co-Director of Faculty Development, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Other Appointments/Responsibilities
Visiting Scientist, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 2016 - 2017
Institutional Committee Activities
Member, Residency Recruitment Committee / Imaging Physics, 2023 - Present
Member, Faculty Recognition Program and Merit Committee / Imaging Physics, 2022 - Present
Member, Culture of Safety Survey Committee / Imaging Physics, 2022 - Present
Honors & Awards
2011 | Young Researcher Travel Award, Synthetic Biology 5.0 Conference, Stanford University, USA |
2010 | Best Poster Award, From Networks to Pattern Formation Symposium, Rice University |
2009 | AMGEN Award in Basic Science Research, UT MDACC |
2008 | Second Prize Poster Award, Systems Biology of Cancer Conference, UT MDACC |
2007 | Postdoctoral Fellowship, Jozef Mianowski Fund and Foundation for Polish Science. Warsaw Poland |
2006 | Ph.D. with Honors, Maria Sklodowska-Curie Memorial Cancer Center, Warsaw, Poland |
2005 | Travel grants, NDDO Research Foundation, Amsterdam, The Netherlands |
2005 | The Best Scientific Work Award, The Vth Conference of Young Scientists / The VIth Russian Oncological Congress |
2005 | Travel grant, European School of Hematology, Paris, France |
2002 | Ph.D. Scholarship, Polish Ministry of Science and Education, Poland |
Selected Publications
Peer-Reviewed Articles
- Nevozhay, D, Rauch, R, Wang, Z, Sokolov, KV. Optimal size and PEG coating of gold nanoparticles for prolonged blood circulation. Nanoscale Advances 7(3):722-727, 2025. e-Pub 2025. PMID: 39811023.
- Mendieta M, Hatami M, Singh M, Fard SS, Dehshiri M, Schill A, Nevozhay D, Aglyamov S, Ozpolat B, Sokolov KV, Akay YM, Larin KV, Akay M. Non-invasive measurement of elasticity in glioblastoma multiforme validates decreased TMZ sensitivity in astrocyte co-culture. IEEE Open J Eng Med Biol, 2025. e-Pub 2025.
- Sehl OC, Yang Y, Anjier AR, Nevozhay D, Cheng D, Guo K, Fellows B, Mohtasebzadeh AR, Mason EE, Sanders T, Kim P, Trease D, Koul D, Goodwill PW, Sokolov K, Wintermark M, Gordon N, Greve JM, Gopalakrishnan V. Preclinical and Clinical-Scale Magnetic Particle Imaging of Natural Killer Cells: in vitro and ex vivo Demonstration of Cellular Sensitivity, Resolution, and Quantification. Mol Imaging Biol 27(1):78-88, 2024. e-Pub 2024. PMID: 39653984.
- Hatami M, Nevozhay D, Singh M, Schill A, Boerner P, Aglyamov S, Sokolov K, Larin KV. Nanobomb optical coherence elastography in multilayered phantoms. Biomed Opt Express 14(11):5670-5681, 2023. e-Pub 2023. PMID: 38021113.
- Kim CS, Nevozhay D, Aburto RR, Pehere A, Pang L, Dillard R, Wang Z, Smith C, Mathieu KB, Zhang M, Hazle JD, Bast RC, Sokolov K. One-Pot, One-Step Synthesis of Drug-Loaded Magnetic Multimicelle Aggregates. Bioconjug Chem 33(5):969-981, 2022. e-Pub 2022. PMID: 35522527.
- Mitcham TM, Nevozhay D, Chen Y, Nguyen LD, Pinton GF, Lai SY, Sokolov KV, Bouchard RR. Effect of Perfluorocarbon Composition on Activation of Phase-Changing Ultrasound Contrast Agents. Med Phys 49(4):2212-2219, 2022. e-Pub 2022. PMID: 35195908.
- Doshi A, Bandey I, Nevozhay D, Varadarajan N, Cirino PC. Design and characterization of a salicylic acid-inducible gene expression system for Jurkat cells. J Biotechnol 346:11-14, 2022. e-Pub 2022. PMID: 35051448.
- Kupczyk P, Simiczyjew A, Marczuk J, Dratkiewicz E, Beberok A, Rok J, Pieniazek M, Biecek P, Nevozhay D, Slowikowski B, Chodaczek G, Wrzesniok D, Nowak D, Donizy P. PARP1 as a Marker of an Aggressive Clinical Phenotype in Cutaneous Melanoma-A Clinical and an In Vitro Study. Cells 10(2):1-21, 2021. e-Pub 2021. PMID: 33572647.
- Boerner P, Nevozhay D, Hatamimoslehabadi M, Chawla HS, Zvietcovich F, Aglyamov S, Larin KV, Sokolov KV. Repetitive optical coherence elastography measurements with blinking nanobombs. Biomed Opt Express 11(11):6659-6673, 2020. e-Pub 2020. PMID: 33282515.
- Nevozhay D, Weiger M, Friedl P, Sokolov KV. Spatiotemporally controlled nano-sized third harmonic generation agents. Biomed Opt Express 10(7):3301-3316, 2019. e-Pub 2019. PMID: 31360600.
- Liu CH, Nevozhay D, Zhang H, Das S, Schill A, Singh M, Aglyamov S, Sokolov KV, Larin KV. Longitudinal elastic wave imaging using nanobomb optical coherence elastography. Opt Lett 44(12):3162-3165, 2019. e-Pub 2019. PMID: 31199406.
- Farquhar KS, Charlebois DA, Szenk M, Cohen J, Nevozhay D, Balázsi G. Role of network-mediated stochasticity in mammalian drug resistance. Nat Commun 10(1):2766, 2019. e-Pub 2019. PMID: 31235692.
- Liu CH, Nevozhay D, Schill A, Singh M, Das S, Nair A, Han Z, Aglyamov S, Larin KV, Sokolov KV. Nanobomb optical coherence elastography. Opt Lett 43(9):2006-2009, 2018. e-Pub 2018. PMID: 29714732.
- Kupczyk P, Reich A, Gajda M, Holysz M, Wysokinska E, Paprocka M, Nevozhay D, Chodaczek G, Jagodzinski PP, Ziólkowski P, Szepietowski JC. UCHL1/PGP 9.5 Dynamic in Neuro-Immune-Cutaneous Milieu: Focusing on Axonal Nerve Terminals and Epidermal Keratinocytes in Psoriatic Itch. Biomed Res Int 2018:7489316, 2018. e-Pub 2018. PMID: 30148172.
- Kupczyk P, Reich A, Holysz M, Gajda M, Wysokinska E, Kobuszewska A, Nevozhay D, Nowakowska B, Strzadala L, Jagodzinski PP, Szepietowski JC. Opioid Receptors in Psoriatic Skin: Relationship with Itch. Acta Derm Venereol 97(5):564-570, 2017. e-Pub 2017. PMID: 27958613.
- Bodi Z, Farkas Z, Nevozhay D, Kalapis D, Lazar V, Csorgo B, Nyerges A, Szamecz B, Fekete G, Papp B, Araujo H, Oliveira JL, Moura G, Santos MAS, Szekely T Jr, Balazsi G, Pal C. Phenotypic heterogeneity promotes adaptive evolution. PLoS Biol 15(5):e2000644, 2017. e-Pub 2017. PMID: 28486496.
- Diao J, Charlebois DA, Nevozhay D, Bódi Z, Pál C, Balázsi G. Efflux Pump Control Alters Synthetic Gene Circuit Function. ACS Synth Biol 5(7):619-31, 2016. e-Pub 2016. PMID: 27111147.
- González C, Ray JC, Manhart M, Adams RM, Nevozhay D, Morozov AV, Balázsi G. Stress-response balance drives the evolution of a network module and its host genome. Mol Syst Biol 11(8):827, 2015. e-Pub 2015. PMID: 26324468.
- Chen L, Noorbakhsh J, Adams RM, Samaniego-Evans J, Agollah G, Nevozhay D, Kuzdzal-Fick J, Mehta P, Balazsi G. Two-dimensionality of yeast colony expansion accompanied by pattern formation. PLoS Comput Biol:e1003979, 2014. e-Pub 2014. PMID: 25504059.
- Nevozhay, D. Cheburator software for automatically calculating drug inhibitory concentrations from in vitro screening assays. PLoS One 9(9):e106186, 2014. e-Pub 2014. PMID: 25184280.
- Goszczynski T, Nevozhay D, Wietrzyk J, Omar MS, Boratynski J. The antileukemic activity of modified fibrinogen-methotrexate conjugate. Biochim Biophys Acta 1830(3):2526-2530, 2013. e-Pub 2013. PMID: 23168301.
- Nevozhay D, Zal T, Balázsi G. Transferring a synthetic gene circuit from yeast to mammalian cells. Nat Commun 4:1451, 2013. e-Pub 2013. PMID: 23385595.
- Nevozhay D, Adams RM, Van Itallie E, Bennett MR, Balázsi G. Mapping the environmental fitness landscape of a synthetic gene circuit. PLoS Comput Biol 8(4):e1002480, 2012. e-Pub 2012. PMID: 22511863.
- Jagiello M, Kanska U, Nevozhay D, Boratynski J. Synthesis and biological activity of raltitrexed-carrier conjugates. Acta Biochim Pol 57(1):83-7, 2010. e-Pub 2010. PMID: 20349025.
- Szczaurska-Nowak K, Dabrowska K, Celka M, Kurzepa A, Nevozhay D, Wietrzyk J, Switala-Jelen K, Syper D, Pozniak G, Opolski A, Gorski A, Radzikowski C. Antitumor effect of combined treatment of mice with cytostatic agents and bacteriophage T4. Anticancer Res 29(6):2361-70, 2009. e-Pub 2009. PMID: 19528503.
- Nevozhay D, Adams RM, Murphy KF, Josic K, Balazsi G. Negative autoregulation linearizes the dose-response and suppresses the heterogeneity of gene expression. Proc Natl Acad Sci U S A 106(13):5123-8, 2009. e-Pub 2009. PMID: 19279212.
- Wietrzyk J, Nevozhay D, Milczarek M, Filip B, Kutner A. Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother Pharmacol 62(5):787-97, 2008. e-Pub 2008. PMID: 18188568.
- Kanska U, Budzynska R, Nevozhay D, Boratynski J. Preparation of mannan-protein conjugates using high-temperature glycation. Biotechnol Appl Biochem 49(Pt 1):57-64, 2008. e-Pub 2008. PMID: 17630955.
- Wietrzyk J, Nevozhay D, Filip B, Milczarek M, Kutner A. The antitumor effect of lowered doses of cytostatics combined with new analogs of vitamin D in mice. Anticancer Res 27(5A):3387-98, 2007. e-Pub 2007. PMID: 17970085.
- Budzynska R, Nevozhay D, Kanska U, Jagiello M, Opolski A, Wietrzyk J, Boratynski J. Antitumor activity of mannan-methotrexate conjugate in vitro and in vivo. Oncol Res 16(9):415-21, 2007. e-Pub 2007. PMID: 18074676.
- Nevozhay D, Budzynska R, Jagiello M, Kanska U, Omar MS, Opolski A, Wietrzyk J, Boratynski J. The effect of the substitution level of some dextran-methotrexate conjugates on their antitumor activity in experimental cancer models. Anticancer Res 26(3A):2179-86, 2006. e-Pub 2006. PMID: 16827162.
- Nevozhay D, Budzynska R, Kanska U, Jagiello M, Omar MS, Boratynski J, Opolski A. Antitumor properties and toxicity of dextran-methotrexate conjugates are dependent on the molecular weight of the carrier. Anticancer Res 26(2A):1135-43, 2006. e-Pub 2006. PMID: 16619515.
- Siwy M, Sek D, Kaczmarczyk B, Jaroszewicz I, Nasulewicz A, Pelczynska M, Nevozhay D, Opolski A. Synthesis and in vitro antileukemic activity of some new 1,3-(oxytetraethylenoxy)cyclotriphosphazene derivatives. J Med Chem 49(2):806-10, 2006. e-Pub 2006. PMID: 16420065.
- Dabrowska K, Opolski A, Wietrzyk J, Nevozhay D, Szczaurska K, Switala-Jelen K, Boratynski J, Gorski A. Activity of bacteriophages in murine tumor models depends on the route of phage administration. Oncol Res 15(4):183-7, 2005. e-Pub 2005. PMID: 17822278.
- Pelczynska M, Wietrzyk J, Jaroszewicz I, Nevozhay D, Switalska M, Kutner A, Zabel M, Opolski A. Correlation between VDR expression and antiproliferative activity of vitamin D3 compounds in combination with cytostatics. Anticancer Res 25(3B):2235-40, 2005. e-Pub 2005. PMID: 16158969.
- Kanska U, Omar MS, Budzynska R, Nevozhay D, Jagiello M, Opolski A, Boratynski J. Antileukemic activity of glycated fibrinogen-methotrexate conjugates. Anticancer Res 25(3B):2229-34, 2005. e-Pub 2005. PMID: 16158968.
- Nawrocka W, Szutuba B, Liszkiewicz H, Kowalska MW, Wietrzyk J, Nevozhay D, Opolski A. Synthesis and antiproliferative activity in vitro of new 2-aminobenzimidazole. Polish J Chem 79:709-716, 2005. e-Pub 2005.
Invited Articles
- Schuemann J, Bagley AF, Berbeco R, Bromma K, Butterworth KT, Byrne HL, Chithrani BD, Cho SH, Cook JR, Favaudon V, Gholami YH, Gargioni E, Hainfeld JF, Hespeels F, Heuskin AC, Ibeh UM, Kuncic Z, Kunjachan S, Lacombe S, Lucas S, Lux F, McMahon S, Nevozhay D, Ngwa W, Payne JD, Penninckx S, Porcel E, Prise KM, Rabus H, Ridwan SM, Rudek B, Sanche L, Singh B, Smilowitz HM, Sokolov KV, Sridhar S, Stanishevskiy Y, Sung W, Tillement O, Virani N, Yantasee W, Krishnan S. Roadmap for metal nanoparticles in radiation therapy: current status, translational challenges, and future directions. Phys Med Biol 65(21):21RM02, 2020. e-Pub 2020. PMID: 32380492.
Other Articles
- Nevozhay D, Kanska U, Budzynska R, Boratynski J [Current status of research on conjugates and related drug delivery systems in the treatment of cancer and other diseases]. Postepy Hig Med Dosw (Online) 61:350-60, 2007. PMID: 17554238.
- Nevozhay D, Opolski A Key factors in experimental mouse hematopoietic stem cell transplantation. Arch Immunol Ther Exp (Warsz) 54(4):253-69, 2006. PMID: 16868724.
Book Chapters
- Nevozhay, D, Bouchard, RR, Sokolov, KV. Photoacoustic Imaging with Plasmonic Nanoparticles. In: World Scientific Reference on Plasmonic Nanomaterials: Principles, Design and Bio-applications, 325-370, 2022.
- Charlebois DA, Diao J, Nevozhay D, Balazsi G. Negative Regulation Gene Circuits for Efflux Pump Control. In: Methods Mol Biol, 25-43, 2018.
- Nevozhay D, Adams RM, Balazsi G. Linearizer gene circuits with negative feedback regulation. In: Yeast Genetic Networks: Methods and Protocols, 81-100, 2011.
- Siwy M, Sek D, Kaczmarczyk B, Jaroszewicz I, Nasulewicz A, Pelczynska M, Nevozhay D, Opolski A. [Macrocyclic cyclophosphazene derivatives with cytostatic activity]. In: [Modification of Polymers], 623-626, 2005.
Selected Presentations & Talks
Local Presentations
- 2017. Using synthetic biology to develop gene expression system. Invited. Stony Brook University. Stony Brook, NY, US.
- 2013. Transferring a synthetic gene circuit from yeast to human cells. Invited. University of Houston. Houston, TX, US.
- 2011. The effects of nongenetic memory on population level sensitivity to stress. Invited. University of Texas-Houston Medical School. Houston, TX, US.
- 2010. Cellular memory and possible stress-induced mutations in yeast cells. Invited. Baylor College of Medicine. Houston, TX, US.
- 2010. Synthetic biology: biology meets engineering. Invited. Rice University. Houston, TX, US.
- 2008. Gene expression noise and feedback regulation in transcriptional cascades. Invited. Rice University. Houston, TX, US.
National Presentations
- 2025. Optimization of nanosized contrast agents for ultrasound imaging. Conference. SPIE Photonics West. San Francisco, CA, US.
- 2016. Developing systems for precise gene expression dosage in lower and higher eukaryotes. Invited. American Chemical Society SWRM. Galveston, TX, US.
- 2012. Decreasing the stochasticity of mammalian gene expression by a synthetic gene circuit. Conference. American Physical Society Annual Meeting. Boston, MA, US.
- 2011. Population-level control of gene expression. Conference. American Physical Society Annual Meeting. Dallas, TX, US.
- 2009. Precise regulation of gene expression by negative feedback. Conference. The 3rd q-bio Conference on Cellular Information Processing. Santa Fe, NM, US.
International Presentations
- 2023. Effect of perfluorocarbon composition on activation of phase-changing ultrasound contrast agents. Invited. Ultrasonics. Caparica, PT.
- 2012. Synthetic biology is the novel genetic engineering. Invited. Pacific Institute of Bioorganic Chemistry, Far Eastern Branch of Russian Academy of Sciences. Vladivostok, RU.
- 2012. Synthetic biology: genetic engineering for the 21st century. Invited. Institute of Immunology and Experimental Therapy. Wroclaw, PL.
- 2005. Effect of calcitriol administration on survival and chimerism after allogeneic BMT in mice. Conference. 3rd Annual Meeting of the European Stem Cell Therapeutics Excellence Centre (STEC). Krakow, PL.
- 2005. The biological properties of different dextran-methotrexate conjugates in tumor models in vitro and in vivo. Conference. The VIth Russian Oncological Congress. Rostov-on-Don, RU.
- 2005. The effect of calcitriol analogue on beta3 integrin-positive tumors. Conference. 2nd Symposium on Vitamin D Analogs in Cancer Prevention and Therapy. Lubeck, DE.
Grant & Contract Support
Date: | 2025 - 2027 |
Title: | MUC16 Imaging for Early Diagnosis of Ovarian Cancer |
Funding Source: | Department of Defense |
Role: | PI |
ID: | GRANT14224761 |
Date: | 2025 - 2027 |
Title: | Ultrasound-guided cancer immunotherapy with targeted nanodroplets |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 1R21CA304638-01 |
Date: | 2025 - 2028 |
Title: | Cancer Prevention Research Institute of Texas (CPRIT |
Funding Source: | Cancer Prevention Research Institute of Texas (CPRIT) |
Role: | Co-I |
ID: | RP250279 |
Date: | 2024 - 2026 |
Title: | Quantitative noncontact imaging of cellular mechanotransduction |
Funding Source: | NIH/NCI |
Role: | Research Assistant Professor |
ID: | 1R21CA297102-01 |
Date: | 2024 - 2026 |
Title: | Perfluorocarbon Nanoparticles 19F MRI to Characterize Space Radiation Induced Acute Pro-Inflamm Response & Anti-Inflamm Effects of Radiation Mitigating Thrombin Peptide to Extend Healthy Life in Space |
Funding Source: | Radiological Society of North America (RSNA) |
Role: | PI |
ID: | RR24‐102 |
Date: | 2024 - 2029 |
Title: | Novel approach to NK cell therapy for recurrent/refractory pediatric medulloblastoma |
Funding Source: | Nevozhay |
Role: | Collaborator |
ID: | 1UG3CA297733-01 |
Date: | 2024 - 2026 |
Title: | Perfluorocarbon Nanoparticles 19F MRI to Characterize Space Radiation Induced Acute Pro-Inflamm Response & Anti-Inflamm Effects of Radiation Mitigating Thrombin Peptide to Extend Healthy Life in Space |
Funding Source: | Radiological Society of North America (RSNA) |
Role: | Mentor |
Date: | 2024 - 2025 |
Title: | Using Perfluorocarbon Nanoparticles 19F MRI to Characterize Space Radiation Induced Acute Pro‐Inflammatory Response and Anti‐Inflammatory Effects of Radiation Mitigating Thrombin Peptide to Extend Healthy Life in Space |
Funding Source: | Radiological Society of North America (RSNA) |
Role: | PI |
ID: | RR24‐102 |
Date: | 2024 - 2029 |
Title: | New approach for osteosarcoma: Enhancing and monitoring NK cell therapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 1P01CA275719-01A1 |
Date: | 2024 - 2028 |
Title: | Priming preclinical magnetic particle Imaging (MPI) for brain Tumor NK Cell tracking in Humans (PITCH) |
Funding Source: | NIH/NCI |
Role: | Co-I |
Date: | 2024 - 2026 |
Title: | Phase-change nanodroplets for ultrasound guided cancer immunotherapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
Date: | 2024 - 2029 |
Title: | Clinical trial of NK cells for pediatric 4th ventricle brain tumors with magnetic particle Imaging (MPI) tracking |
Funding Source: | NIH/NCI |
Role: | Collaborator |
Date: | 2024 - 2026 |
Title: | Noncontact biomechanical characterization of cellular mechanotransduction |
Funding Source: | NIH/NCI |
Role: | Assistant Professor |
Date: | 2024 - 2027 |
Title: | Next-generation high-Z nanoparticle radiosensitizers to advance combination cancer therapies |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Co-I |
ID: | RP240156 |
Date: | 2024 - 2026 |
Title: | NK Immunotherapy for DIPG |
Funding Source: | Children's Cancer Research Fund |
Role: | Collaborator |
Date: | 2023 - 2028 |
Title: | Clinical trial of NK cells for pediatric 4th ventricle brain tumors with magnetic particle Imaging (MPI) tracking |
Funding Source: | NIH/NCI |
Role: | Collaborator |
ID: | 1UG3CA283650-01 |
Date: | 2023 - 2024 |
Title: | Preclinical magnetic particle Imaging (MPI) for brain Tumor NK Cell tracking |
Funding Source: | Elsa U. Pardee Foundation |
Role: | Co-I |
ID: | 20546 |
Date: | 2023 - 2025 |
Title: | Noncontact biomechanical characterization of cellular mechanotransduction |
Funding Source: | NIH/NCI |
Role: | Collaborator |
ID: | 1R21CA283430-01 |
Date: | 2023 - 2028 |
Title: | Priming preclinical magnetic particle Imaging (MPI) for brain Tumor NK Cell tracking in Humans (PITCH) |
Funding Source: | NIH/NCI |
Role: | Collaborator |
ID: | 1R01CA281832-01 |
Date: | 2023 - 2026 |
Title: | NK Immunotherapy for DIPG |
Funding Source: | ChadTough Defeat DIPG Foundation |
Role: | Collaborator |
Date: | 2023 - 2025 |
Title: | Hyperpolarized 129Xe MRI for imaging NK cell therapy of lung metastasis |
Funding Source: | NIH/NCI |
Role: | Instructor |
ID: | 5R21CA280799-02 |
Date: | 2023 - 2027 |
Title: | Next-generation high-Z nanoparticle radiosensitizers to advance combination cancer therapies |
Funding Source: | NIH/NCI |
Role: | Instructor |
ID: | 1R01CA274955-01A1 |
Date: | 2022 - 2027 |
Title: | New Approach for Osteosarcoma: Enhancing and Monitoring NK Cell Therapy |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 1P01CA2757190-01 |
Date: | 2022 - 2026 |
Title: | NO TITLE PROVIDED |
Funding Source: | NIH |
Role: | Instructor |
ID: | 1R01CA274955-01 |
Date: | 2022 - 2027 |
Title: | Using Stealth Gold Nanoparticles to Improve Radiation Therapy |
Funding Source: | NIH |
Role: | Co-I |
ID: | 1P01CA257932-01A1 |
Date: | 2022 - 2027 |
Title: | Unraveling dynamic co-evolutions of brain metastasis and the unique brain microenvironment |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 1U54CA261702-01A1 |
Date: | 2022 - 2025 |
Title: | Translatable Molecular Ultrasound Imaging of Cancer Metastasis Using Targeted Phase-change Nanodroplets |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
ID: | RP220379 |
Date: | 2021 - 2026 |
Title: | Unraveling dynamic co-evolutions of brain metastasis and the unique brain microenvironment |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 1U54CA261702-01 |
Date: | 2021 - 2023 |
Title: | Development of fluorinated dyes for deeper tissue photoacoustic imaging with phase changing nanodroplets |
Funding Source: | NIH/NIBIB |
Role: | Collaborator |
ID: | 1R21EB030805-01A1 |
Date: | 2021 - 2026 |
Title: | Stealth nanoscale armored particles for radiosensitization of head and neck tumors |
Funding Source: | NIH/NCI |
Role: | Collaborator |
ID: | 1R01CA264096-01 |
Date: | 2020 - 2025 |
Title: | Shielded gold nanoparticles with greatly improved pharmacokinetics for radiosensitization of head and neck tumors |
Funding Source: | NIH/NIDCR |
Role: | Co-I |
ID: | 1R01DE030017-01A1 |
Date: | 2020 - 2022 |
Title: | Development of antibody-conjugated magnetic liposomal nanoparticles for early detection of ovarian Cancer by magnetic relaxometry |
Funding Source: | Internal- Moonshot |
Role: | Co-I |
Date: | 2020 - 2021 |
Title: | Tumor heterogeneity in immune sensitivity of DIPGs |
Funding Source: | Chance of Life Foundation |
Role: | Co-I |
Date: | 2020 - 2023 |
Title: | High sensitivity 19F MRI for clinically translatable imaging of adoptive NK cell brain tumor therapy |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Instructor |
ID: | RP200223 |
Date: | 2019 - 2022 |
Title: | CAR-NK Adoptive Cell Therapy for Osteosarcoma |
Funding Source: | UTMDACC - MRP |
Role: | Collaborator |
Date: | 2019 - 2023 |
Title: | Neoadjuvant treatment response monitoring of breast cancer with molecular photoacoustic imaging |
Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
Role: | Collaborator |
ID: | RP190131 |
Date: | 2019 - 2022 |
Title: | 3D Imaging of Tumor Mechanobiology Using Nanobomb Optical Coherence Elastography |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 5R21CA231561-02 |
Date: | 2018 - 2021 |
Title: | Targeted Phase-change Nanodroplets for Translatable Molecular Ultrasound Imaging of Micrometastases |
Funding Source: | NIH/NCI |
Role: | Co-I |
ID: | 5R21CA234526-02 |
Date: | 2018 - 2020 |
Title: | MRI imaging of adoptive NK Cell immunotherapy |
Funding Source: | MD Anderson Cancer |
Role: | Research Scientist |
ID: | IRG-Institutional Research Grant |
Date: | 2012 - 2017 |
Title: | K99/R00 Pathway to Independence Award; Development of inducible mammalian systems for precise and dose-dependent regulation of gene expression |
Funding Source: | NIH/NIBIB |
Role: | PI |
ID: | 1K99B015723-01 |
Patient Reviews
CV information above last modified April 16, 2025